Displaying drugs 13376 - 13400 of 14517 in total
Bifidobacterium spp.
Investigational
Lactobacillus brevis
Investigational
SIG-205
SIG-205 is a Cultured human retinal pigment epithelial cells (ARPE-19) genetically modified with a non-viral vector to express human native alpha-L-iduronidase enzyme (hIDUA), encapsulated within two-layer modified alginate spheres
Investigational
OSSM-007
OSSM-007 consists of interferon-gamma primed allogeneic mesenchymal stem cells.
Investigational
ETX101
ETX101 is a non-replicating recombinant adeno associated viral vector, serotype 9, designed to promote increased transcription of SCN1A gene.
Investigational
PBGM01
PBGM01 is a non-replicating recombinant adeno-associated virus serotype hu68 vector, which contains human GLB1 transgene encoding the galactosidase beta 1 enzyme.
Investigational
CTR-107
CTR-107 is a synthetic targeted growth factor. It is being investigated for the treatment of familial exudative vitreoretinopathy.
Investigational
Recombinant neuroglobin
Investigational
TSHA-102
TSHA-102 is a recombinant serotype 9 adeno-associated virus encoding a codon-optimized human MECP2 gene.
Investigational
Alpha-1-acid glycoprotein
Investigational
ECT204
ECT204 is an autologous T-cell therapy whereby T cells are genetically modified to target tumor-specific antigens.
Investigational
Sapablursen
Sapablursen is a synthetic 2'-O-(2-methoxyethyl)-modified antisense oligonucleotide linked to a tri-antennary cluster of N-acetyl galactosamine (GalNAc3) sugars targeting transmembrane protease, serine 6 messenger ribonucleic acid
Investigational
CTX130
CTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.
Investigational
Allogeneic natural killer cells
Investigational
AVR-RD-05
AVR-RD-05 is a gene therapy comprising genetically modified autologous stem cells transduced ex vivo with a lentiviral vector encoding the human iduronate-2-sulfatase (IDS) enzyme. It is under investigation for the treatment of Hunter Syndrome (Mucopolysaccharidosis Type II, MPSII).
Investigational
MaaT013
MaaT013 is an allogeneic fecal microbiota therapy. It is being investigated for the treatment of Graft-Versus-Host Disease.
Investigational
Allogeneic human pancreatic islets of Langerhans
Investigational
ssCART-19 cells
ssCART-19 cells consist of autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6).
Investigational
Displaying drugs 13376 - 13400 of 14517 in total